Scancell Holdings PLC is presenting encouraging data from its ongoing Phase II clinical trial of SCIB1, an experimental melanoma vaccine, at the American Association for Cancer Research Immuno-Oncology (AACR IO) conference in Los Angeles. The data highlights the vaccine's mechanism of action and its effectiveness when combined with the widely used cancer drugs nivolumab and ipilimumab.
SCIB1: A Novel Approach to Melanoma Treatment
SCIB1 is a DNA-based cancer vaccine designed to stimulate the immune system to identify and destroy melanoma cells. The SCOPE study is evaluating SCIB1 in conjunction with checkpoint inhibitors, drugs that enhance the immune system's ability to attack cancer cells. This combination therapy aims to provide a more robust and targeted approach to treating advanced melanoma.
Promising Early Results
Initial results from 25 patients in the SCOPE trial demonstrate encouraging outcomes. The data indicates that 84% of patients experienced disease control, with 80% remaining progression-free. Notably, 20% of patients achieved a complete response, indicating no detectable signs of cancer following treatment.
Deeper Insights into Immune Activation
The data presented at the AACR IO conference offers a more detailed understanding of how SCIB1 activates the body’s immune T cells to combat melanoma. These findings are crucial as they validate the vaccine's efficacy and support its continued development as a potential new treatment option for advanced melanoma.
Expert Commentary
"Presenting data showing vaccine-specific T cell responses at AACR IO is an important validation of SCIB1 efficacy in advanced melanoma," said Scancell CEO Phil L'Huillier. "This data supports the latest findings from the phase II Scope trial, evaluating SCIB1 in combination with CPIs. We look forward to sharing the latest insights with leading industry experts at AACR IO."
